Today's Peptide News — July 25, 2026

G protein-coupled receptors are the single largest class of drug targets, and a new Nature Reviews Methods Primer argues that peptides have quietly become one of the most versatile ligand types for probing them. The authors walk through the full modern discovery stack — in silico peptide mining, deorphanization of orphan receptors, combinatorial and display-based library screening, computational design, and the chemical strategies used to stabilize otherwise fragile peptide leads.

The piece matters because it consolidates a fast-moving field into a single reference, effectively giving medicinal chemists a map for turning a receptor of interest into a screenable peptide campaign. For a PeptideWiki post, the strong angle is explainer-style: "Why peptides are becoming the go-to tool for cracking GPCR drug targets," using the primer to frame how library screening and computational design now feed directly into today's metabolic and cardiovascular peptide drugs.

A bioRxiv preprint describes a structure-guided pipeline that produced peptide inhibitors aimed not at killing fungi outright, but at switching off the secreted peptidases the pathogens use to attack host tissue and evade drugs. The designed inhibitors showed potent antifungal activity while sparing mammalian cells, and the authors propose a predictive framework for rationally designing next-generation antifungals that "disarm" the pathogen so the immune system can clear it.

This is a compelling story because antifungal resistance is a growing and under-covered threat, and a virulence-disarming approach is mechanistically different from conventional membrane-lysing antifungals. A good PeptideWiki angle is mechanism-focused: "Disarm, don't kill — how designer peptides target fungal virulence instead of the fungus," emphasizing the rational-design workflow and the selectivity that keeps host cells unharmed.

Antimicrobial peptide discovery has leaned heavily on machine-learning predictors, but the field has lacked a clean way to compare them. The BATTLE-AMP bioRxiv preprint introduces a standardized benchmark for evaluating antimicrobial peptide predictors head-to-head, surfacing where popular models agree, where they fail, and how much their reported performance depends on the datasets they were trained and tested on.

The finding matters because it injects a dose of rigor into an area where impressive-sounding accuracy numbers are easy to overstate, and it gives researchers a shared yardstick before they commit resources to synthesizing candidates. For PeptideWiki, the natural angle is a reality-check explainer: "Can AI really pick winning antimicrobial peptides? A new benchmark grades the tools," useful for readers who see a lot of AI-peptide hype and want to know what actually holds up.

The FDA approved Merck's LIPFENDRA (enlicitide) as an adjunct to diet and exercise for lowering LDL cholesterol, marking the first once-daily oral macrocyclic peptide PCSK9 inhibitor to reach the market. Phase 3 data cited around the approval showed roughly 56–59% reductions in LDL-C, and the drug is priced at about $315 per month — positioning an oral peptide against the injectable antibodies that have dominated PCSK9 inhibition.

The approval is significant because PCSK9 inhibition has been effective but shackled to injections, and an oral macrocyclic peptide that survives the gut is a genuine formulation milestone. A strong PeptideWiki angle: "How a macrocyclic peptide cracked oral PCSK9 inhibition," explaining what macrocyclization does for oral stability and why this could widen access to aggressive cholesterol lowering.

Boehringer Ingelheim began a Phase 2 trial of BI 3034701, an investigational peptide that simultaneously activates the GLP-1, GIP, and neuropeptide Y2 (NPY2) receptors in people with obesity and overweight. The design pairs the appetite- and metabolism-regulating effects of GLP-1/GIP with NPY2-mediated modulation of central hunger signaling, making it a potential first-in-class triple agonist discovered with partner Gubra.

The move matters because obesity drug development is racing past single- and dual-agonist peptides toward multi-receptor designs, and adding an NPY2 arm is a novel mechanistic bet on central appetite control. For PeptideWiki, a good angle is a pipeline explainer: "Beyond dual agonists — what a GLP-1/GIP/NPY2 triple agonist is trying to do," situating BI 3034701 alongside retatrutide and other next-generation weight-loss peptides.

The FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026 to review BPC-157, TB-500, and several other peptides for possible inclusion on the 503A bulk compounding list. The outcome bears directly on whether compounding pharmacies can legally prepare these popular "research" peptides for patients, an area that has grown rapidly amid demand for recovery, healing, and performance applications despite thin clinical evidence.

The story is relevant to PeptideWiki's core audience because BPC-157 and TB-500 are among the most-searched peptides yet sit in a regulatory gray zone. A timely angle: "What the FDA compounding review means for BPC-157 and TB-500," laying out what a 503A listing (or rejection) would practically change for access, safety oversight, and the marketing claims around these peptides.

Researchers at USC's Keck School of Medicine, with international collaborators, published the largest genetic study to date of hyperemesis gravidarum — the most severe form of pregnancy nausea and vomiting — in Nature Genetics. Analyzing more than 10,000 affected women against roughly 461,000 controls across European, Asian, African, and Latino ancestries, they identified nine additional risk genes, six never previously linked to the condition, several tied to appetite, nausea, metabolism, and brain function.

The findings matter because hyperemesis gravidarum can be debilitating and is often dismissed, and pinpointing genes in appetite and nausea pathways points toward more targeted treatments. The multi-ancestry design also strengthens confidence that the signals generalize beyond European populations, a recurring weakness in genetic studies.

Research presented at the American Heart Association's Basic Cardiovascular Sciences Scientific Sessions 2026 linked Porphyromonas gingivalis, the primary driver of serious gum disease, to calcific aortic valve stenosis. The bacterium was found at elevated concentrations in calcified human valves compared with non-calcified ones, and in mice, repeated exposure led to bacterial accumulation in the aortic valve, increased calcification, and stenosis symptoms via activation of the IL-1β inflammatory pathway; preventive antibiotics blunted these effects.

The work is notable because there are currently no drugs proven to slow calcific aortic valve stenosis, which is typically treated only by valve replacement. If an oral bacterium is helping drive valve calcification through inflammation, it raises the possibility that treating gum disease could become part of protecting the heart — though these are preliminary, mostly preclinical findings that still need human confirmation.

Umeå University researchers reported in Signal Transduction and Targeted Therapy a fully human antibody that halted the growth and spread of castration-resistant prostate cancer in preclinical models. The antibody blocks oncogenic signaling driven by the TGF-beta type I receptor (TβRI) and inhibited both primary tumor growth and metastasis in an aggressive, hormone-therapy-resistant form of the disease.

The result is promising because the antibody is composed entirely of human proteins, lowering the immunogenicity hurdles that complicate many biologics and making it more plausible as a therapeutic. Castration-resistant prostate cancer that spreads to lymph nodes and bone has few good options, so an antibody with an unusual TβRI-targeting mechanism could open a safer avenue — pending the human testing that preclinical success still requires.